Professional Documents
Culture Documents
Toxin Gene Expression by Shiga Toxin-Producing Escherichia coli the Role of Antibiotics and the Bacterial SOS Response
Toxin Gene Expression by Shiga Toxin-Producing Escherichia coli the Role of Antibiotics and the Bacterial SOS Response
The associations between Escherichia coli strains are more closely associated with HUS
O157:H7 infection, hemorrhagic colitis, and than are strains that produce only Stx1 (5,6).
hemolytic uremic syndrome (HUS) were estab- Because antimicrobial agents may play a role
lished in the early 1980s (1,2). Shiga toxin- in the pathogenesis of severe STEC disease,
producing E. coli (STEC) strains have since been chemotherapy for STEC infections remains
recognized as the cause of both outbreaks and controversial (7,8). The location of stx genes
sporadic cases of diarrhea and HUS, involving (predominantly on λ-like bacteriophage genomes
thousands of cases and numerous deaths (3). integrated into the chromosome of their host
Shiga toxins are key virulence factors in the bacterium) has important implications because
pathogenesis of STEC disease (3). The term Shiga the induction of the SOS response, an extensively
toxin (Stx) refers to two families of related toxins, characterized genetic regulatory mechanism,
Stx/Stx1, which includes the classical Shiga toxin induces high-level expression of previously silent
produced by Shigella dysenteriae, and Stx2 (4). bacteriophage genes (9). Stx genes are coexpressed
The stx genes carried by STEC strains are, with with genes of the bacteriophage (10,11), and
one possible exception (stx2e), encoded on certain quinolones (known to be potent SOS
bacteriophage genomes integrated into the inducers) induce increases in toxin (12,13) and
bacterial chromosome. Stx2-producing STEC bacteriophage production (13) of two to three
orders of magnitude within 2 to 4 hours. The
Address for correspondence: M.R. Barer, Department of potential importance of a link between the SOS
Microbiology and Immunology, University of Newcastle, The
Medical School, Framlington Place, Newcastle upon Tyne,
response and prophage induction for Stx1 and
NE2 4HH, United Kingdom; Fax: +44 191 222 7736; e-mail: Stx2 expression has been reinforced by recent
m.r.barer@ncl.ac.uk. sequencing and pathogenicity studies (11,14,15).
(30 µg), cefuroxime (5 µg), piperacillin/tazobactam min. ß-galactosidase activity was determined by
(10/75 µg), ampicillin (10 µg), cephalexin (30 µg), using the linear portion of the corrected OD420 /
chloramphenicol (30 µg), doxycycline (30 µg), time relationship by the Miller formula, adjusted
erythromycin (15 µg), trimethoprim (5 µg), for the sample volume (16). Replicate samples (at
sulphamethoxazole (25 µg), furazolidone (50 µg), least four in all assays reported) yielded mean
amoxicillin (25 µg), novobiocin (30 µg), rifampin values with coefficients of variation <10% in all
(25 µg), gentamicin (10 µg), fosfomycin (200 µg) cases.
(oral and systemic salts), polymyxin B (300 IU),
and metronidazole (50 µg). Results
The Bioscreen C system was also used to All the quinolones induced reporter expres-
measure total ß-galactosidase activity in whole sion, while only a few of the other agents had this
cultures of strain PK552 by orthonitrophenyl-ß- effect (Figure 1). The induction occurred in three
D-galactoside (ONPG) assay (16). Aliquots general patterns: a defined zone within the zone
(20 µL, 4 replicates) of culture were removed of growth inhibition (quinolones), a defined zone
from wells of the honeycomb plate and added to a at the growth/no growth interface (furazolidone),
fresh plate. To this, 180 µL of Z buffer (60 mM or a diffuse zone within the zone of inhibition
Na2HPO4 7H2O, 40 mM NaH2PO4 H2O, 10 mM (trimethoprim). In addition, the incubation condi-
KCl, 1 mM MgSO4, and 50 mM ß-mercaptoethanol, tions appeared to produce a background level of
pH 7.0) containing 2 mg/mL lysozyme, 0.01% induction or suppression. Microaerobic condi-
sodium dodecyl sulfate (SDS), and 100 µg/mL tions and to a lesser extent incubation at 30°C
chloramphenicol was added to the cells. The plate were associated with background induction,
was incubated at 37°C for 30 min to lyse the cells while anaerobic conditions and incubation at
and placed on ice until use. The Bioscreen C 42°C had a suppressive effect as determined by
system was prewarmed to 28°C, and 40 µL of 4 the intensities of the blue zones. However, some
mg/mL ONPG solution (made up in Z buffer) was quinolone-mediated induction was always detect-
added to each well. Plates were incubated in the able, even under the most suppressive condition
Bioscreen C system at 28°C for 4 hours, and OD (42°C). Induction by furazolidone and trimethop-
was recorded at both 420 nm and 540 nm every 10 rim was, in general, similarly enhanced and
Figure 1. Zones of stx2 expression induced by various antimicrobial agents under different incubation conditions.
The disc-diffusion assay plates demonstrate background levels and zones of blue coloration related to reporter
gene β-galactosidase activity produced by our reporter strain. Digital images were acquired and processed
identically. Color was encoded by the CMYK system, and only the cyan component is displayed as a gray-scale
image. Blue zones appear as lighter areas of the plate, the intensity of which represents the blue intensity as
judged by direct comparison. Abbreviations: mO2, microaerobic and AnO2, anaerobic incubation conditions;
numbers denote incubation temperatures ( C). Left panel, quinolones (clockwise from top): ofloxacin, nalidixic
acid, cinoxacin, enrofloxacin, flumeqine, ciprofloxacin, perfloxacin, and norfloxacin. Right panel, other oral
agents (clockwise from top): trimethoprim, erythromycin, doxycycline, chloramphenicol, cephalexin, amoxycillin,
furazolidone, and sulphamethoxazole.
protein leads to the induction of previously silent C administration and HUS was detected in a
phage-encoded genes (in this case including study of “cancer-associated” HUS (29).
stx2A and stx2B), followed by production of phage Grif and colleagues reported on the effects of
particles and host bacterial cell lysis (9). sub-MIC levels of 13 antibiotics on release of
The most potent SOS inducers, the quinolones biologically active toxin (as distinct from toxin gene
and trimethoprim, produced the most prominent expression) by three STEC strains into culture
effects in both agar and liquid culture assays. supernatants after overnight incubation (20).
Metronidazole did not induce reporter expression These authors observed substantial interstrain
under the conditions tested; however, this agent differences in the responses, as well as increased
would not normally be expected to affect E. coli. levels of toxin after exposure to several agents
Another potent SOS inducer, mitomycin C, which that had not previously been associated with
is known to increase toxin levels in vitro (24,25), SOS-inducing activity. Grif et al. did not
tests positive in agar and broth induction tests distinguish between enhanced release of pre-
with our reporter strain (results not shown). formed toxin and increased toxin production, and
The potential importance of the SOS response to the most potent inducing effects we have
pathogenesis in vivo has recently been under- observed were at suprainhibitory levels of
lined by a study in which STEC strains with exposure. Nonetheless, we cannot rule out
mutations in recA, a critical gene for SOS interstrain differences in susceptibility to SOS
induction, were rendered avirulent in a mouse activation and the possibility that other
50% lethal dose test (15). induction mechanisms may be involved. Our
The importance of antibiotic-induced Stx observations on SOS induction by several
expression would be reinforced if the implicated ß-lactam agents and the inhibitory effects of
agents were in some way associated with imipenem appear pertinent. Suppression of toxin
occurrence or severity of STEC disease. The expression by imipenem supports previous
results of available studies have conflicted with observations on toxin release (30). Paired disc-
regard to the influence of antibiotics. The age diffusion assays involving imipenem and other
groups studied, the timing of antibiotic therapy, recognized SOS-inducing antibiotics indicated
and the range of agents used complicate the that this effect was confined to induction by
analyses. Nonetheless, use of quinolones and ß-lactam agents (Kimmitt, Harwood, and Barer,
trimethoprim/sulphamethoxazole (26,27) has unpubl data). This finding, combined with the
been implicated as a risk factor for HUS. In a different time course of induction with ce-
recent clinical study, children treated with furoxime, reinforces the view that there may be
cephalosporins or trimethoprim-sulphamethox- induction pathways distinct from the SOS
azole had, respectively, 13.4- and 17.7-fold response. Although the nature of the putative
increases in risk for HUS (28). Our observations alternate induction pathway(s) remains obscure,
suggest that the net effect of one of these agents the clear evidence for ß-lactam-mediated induc-
on the exposure of an infected patient to toxin tion may contraindicate use of the implicated
depends on the stage of the infection, the number agents in treating patients with STEC infection.
of organisms present at the time antibiotics are Although any increase in exposure of STEC-
administered, the immediate environmental infected persons to Shiga toxins seems undesir-
conditions of those organisms, and the time- able, SOS-mediated induction seems particularly
concentration profile and bactericidal effect of hazardous because of its potential rapid effects.
the drug. This complex interplay of factors could We report kinetics (Figure 3) somewhat slower
render an SOS-inducing antibiotic clinically than those we observed previously in the shaken
beneficial (e.g., if the numbers of infecting conical flask incubations (12). The rapid buildup
organisms were insufficient to produce substan- in toxin levels associated with SOS induction
tial amounts of toxin and they were all killed by could facilitate entry of toxin into the blood-
the first dose), neutral, or disadvantageous in stream and subsequent disseminated effects on
different situations. Moreover, exposure of the kidneys and other organs. SOS-mediated
patients to other potential SOS-inducing agents induction also leads to dissemination of the toxin-
(cf. 9,23) could further complicate the relation- encoding bacteriophage.
ship between antibiotic use and severe STEC Matsushiro et al. observed parallel increases
disease. A strong association between mitomycin in toxin and bacteriophage counts in response to
norfloxacin (13), and we have made similar 2. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG,
observations with ofloxacin and trimethoprim Davis BR, et al. Hemorrhagic colitis associated with a rare
Escherichia coli serotype. N Engl J Med 1983;308:681-5.
(Kimmit, Harwood and Barer, unpubl data).
3. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet
Moreover, sequencing studies clearly indicate 1998;352:1207-12.
that expression of stx2 and bacteriophage 4. Acheson DW. Nomenclature of enterotoxins. Lancet
genes is coordinately regulated (11,14). Hemor- 1998;351:1003.
rhagic colitis and HUS attributable to STEC 5. Scotland SM, Willshaw GA, Smith HR, Rowe B.
Properties of strains of Escherichia coli belonging to
were recognized after trimethoprim and the 4-
serogroup O157 with special reference to production of
quinolones were introduced into human and Vero cytotoxins VT1 and VT2. Epidemiol Infect
veterinary clinical practice, and the substantial 1987;99:613-24.
recent increase in reports of STEC disease 6. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean
follows expanded use of fluoroquinolones. N, Kobayashi JM. Toxin genotypes and plasmid profiles as
determinants of systemic sequelae in Escherichia coli
Fluoroquinolones and trimethoprim have
O157:H7 infections. J Infect Dis 1989;160:994-8.
been recommended for prophylaxis and treatment 7. Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin
of travelers’ diarrhea (31), and the former are JC, Karmali MA, et al. A severe outbreak of Escherichia
often used to treat severe bacterial enteric coli O157:H7-associated hemorrhagic colitis in a
infections. Our findings indicate that this approach nursing home. N Engl J Med 1987;317:1496-500.
8. Proulx F, Seidman E. Is antibiotic therapy of mice and
may be inappropriate if STEC infection is a
humans useful in Escherichia coli O157:H7 enteritis?
possibility. Furthermore, reports that certain European J Clin Microbiol Infect Dis 1999;18:533-4.
antimicrobial agents may ameliorate or reduce 9. Walker GC. The SOS response of Escherichia coli. In:
symptoms or the frequency of life-threatening F.C. Neidhardt, editor. Escherichia coli and Salmonella.
complications in STEC infections provide an Washington: ASM Press; 1996. p. 1400-16.
10. Muhldorfer I, Hacker J, Keusch GT, Acheson DW, Tschape
incentive to find a rational basis for selection
H, Kane AV. Regulation of the Shiga-like toxin II operon in
(8,27). Our results suggest that agents with SOS- Escherichia coli. Infect Immun 1996;64:495-502.
inducing activity, antimicrobial or otherwise, 11. Neely MN, Friedman DI. Functional and genetic
should be avoided (Table). analysis of regulatory regions of coliphage H-19B:
We conclude that SOS-mediated induction of location of shiga-like toxin and lysis genes suggest a
role for phage functions in toxin release. Mol Microbiol
Shiga toxins and toxin–encoding bacteriophages
1998;28:1255-67.
may contribute to the emerging epidemiologic 12. Kimmitt PT, Harwood CR, Barer MR. Induction of type
pattern of STEC disease. Many other bacterial 2 shiga toxin synthesis in Escherichia coli O157 by 4-
virulence determinants are encoded on lysogenic quinolones. Lancet 1999;353:1588-9.
bacteriophage genomes (32), and the issues 13. Matsushiro A, Sato K, Miyamoto H, Yamamura T,
Honda T. Induction of prophages of enterohemorrhagic
raised here may have public health and clinical
Escherichia coli O157:H7 with norfloxacin. J Bacteriol
implications beyond the understanding of 1999;181:2257-60.
STEC disease. 14. Plunkett G, Rose DJ, Durfee TJ, Blattner FR. Sequence
of Shiga toxin 2 phage 933W from Escherichia coli
Acknowledgments O157:H7: Shiga toxin as a phage late-gene product. J
We thank D. Jenkins for providing strain RV31 from a Bacteriol 1999;181:1767-78.
patient with hemorrhagic diarrhea. 15. Fuchs S, Muhldorfer I, Donohue-Rolfe A, Kerenyic M,
Emody L, Alexiev R, et al. Influence of RecA on in vivo
This work was funded by The Department of Health, virulence and Shiga toxin 2 production in Escherichia
London (DH 243). coli pathogens. Microb Pathog 1999;27:13–23.
16. Miller JH. Experiments in molecular genetics. Cold Spring
Dr. Kimmitt is trained in medical microbiology and Harbor (NY): Cold Spring Harbor Laboratory; 1972.
molecular biology. He is currently studying the molecu- 17. Karch H, Strockbine NA, O’Brien AD. Growth of
lar biology of chlamydia infection at the London School Escherichia coli in the presence of trimethoprim-
of Hygiene and Tropical Medicine. sulfamethoxazole facilitates detection of Shiga-like
toxin producing strains by colony blot assay. FEMS
Microbiol Lett 1986;35:141-5.
References 18. Yoh M, Frimpong EK, Honda T. Effect of
1. Karmali MA, Petric M, Lim C, Fleming PC, Steele BT. antimicrobial agents, especially fosfomycin, on the
Escherichia coli cytotoxin, haemolytic-uraemic syndrome, production and release of Vero toxin by enterohaem-
and haemorrhagic colitis. Lancet 1983;2:1299-300. orrhagic Escherichia coli O157:H7. FEMS Immunol
Med Microbiol 1997;19:57-64.
19. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. 27. Dundas S, Todd WTA. Clinical presentation,
Effect of subinhibitory concentrations of antibiotics on complications and treatment of infection with
extracellular Shiga-like toxin-I. Infection 1992;20:25-9. verocytotoxin producing Escherichia coli. Challenges
20. Grif K, Dierich MP, Karch H, Allerberger F. Strain- for the clinician. J Appl Microbiol 2000;88:24S-30S.
specific differences in the amount of Shiga toxin 28. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI.
released from enterohaemorrhagic Escherichia coli The risk of the hemolytic-uremic syndrome after
O157 following exposure to subinhibitory concentrations antibiotic treatment of Escherichia coli O157:H7
of antimicrobial agents. Eur J Clin Microbiol Infect Dis infections. N Engl J Med 2000;342(26):1930-6.
1998;17:761-6. 29. Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R,
21. Drlica K, Zhao XL. DNA gyrase, topoisomerase IV, and the Keller J, et al. Cancer-associated hemolytic -uremic
4-quinolones. Microbiol Mol Biol Rev 1997;61:377-94. syndrome: analysis of 85 cases from a national registry.
22. Lewin CS, Amyes SG. The role of the SOS response in J Clin Oncol 1989;115:781-9.
bacteria exposed to zidovudine or trimethoprim. J Med 30. Takahashi K, Narita K, Kato Y, Sugiyama T, Koide N,
Microbiol 1991;34:329-32. Yoshida T, et al. Low-level release of Shiga-like toxin
23. Quillardet P, Hofnung M. The SOS chromotest: a (verocytotoxin) and endotoxin from enterohemorrhagic
review. Mutat Res 1993;297:235-79. Escherichia coli treated with imipenem. Antimicrob
24. Yee AJ, De Grandis S, Gyles CL. Mitomycin-induced Agents Chemother 1997;41:2295-6.
synthesis of a Shiga-like toxin from enteropathogenic 31. Health Information for International Travel 1999-
Escherichia coli H.I.8. Infect Immun 1993;61:4510-13. 2000. Atlanta: Centers for Disease Control and
25. al-Jumaili I, Burke DA, Scotland SM, al-Mardini H, Prevention;1999. p. 168.
Record CO. A method of enhancing verocytotoxin 32. Cheetham BF, Katz ME. A role for bacteriophages in
production by Escherichia coli. FEMS Microbiol Lett the evolution and transfer of bacterial virulence
1992;72:121-5. determinants. Mol Microbiol 1995;18:201-8.
26. Pavia AT, Nichols CR, Green DP, Tauxe RV, Mottice S,
Greene KD, et al. Hemolytic-uremic syndrome during an
outbreak of Escherichia coli O157:H7 infections in
institutions for mentally retarded persons: clinical and
epidemiologic observations. J Pediatr 1990;116:544-51.